Selected Grants
IRIS-CKD Implementation pRogram to Improve Screening and management for CKD in diabetes
Clinical TrialPrincipal Investigator · Awarded by DCRI-Duke-Site · 2025 - 2030CSL Behring CSL300_2301 - a 2-part (phase 2b / 3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study.
Clinical TrialPrincipal Investigator · Awarded by CSL Behring LLC · 2025 - 2030Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients Treated with Hemodialysis (PEARL-HD)
Clinical TrialPrincipal Investigator · Awarded by Vifor Pharma, Inc · 2019 - 2025A Prospective, RanDomized, Multi-Center, Open-Label, Cross-Over Study of Sodium Zirconium Cyclosilicate to Control Interdialytic HyperkalemiA Following Augmentation of DialysatePotassium: Efficacy to Reduce the Incidence of Post-Dialysis Atrial Fib
Clinical TrialPrincipal Investigator · Awarded by NephroNET, Inc · 2022 - 2025Duke Training Grant in Nephrology
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1995 - 2023A Randomized Trial of Fistula vs. Graft Arteriovenous Vascular Access in Older Adults with End-Stage Kidney Disease on Hemodialysis: The AV ACCESS Trial
Clinical TrialPrincipal Investigator · Awarded by Wake Forest University School Of Medicine · 2021 - 2023Preventing Cognitive Decline by Reducing BP Target Trial (PCOT)
ResearchCo Investigator · Awarded by University of Texas - Southwestern · 2020 - 2021Protocol No. 28431754DNE3001: "A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy"
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2014 - 2019Oral Sodium Bicarbonate to Slow Chronic Kidney Disease Progression
ResearchPrincipal Investigator · Awarded by University of Utah · 2017 - 2018Data Coordinating Center for Pilot Studies of Candidate Therapies for CKD
ResearchPrincipal Investigator · Awarded by Cleveland Clinic Lerner College of Medicine · 2013 - 2018NephroGenex Protocol PRY-311 : A Phase 3 Randomized, Double-Blind,Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (pyridoxamine dihydrochloride) in Subjects With Nephropathy Due to Type 2 Diabetes.
Clinical TrialPrincipal Investigator · Awarded by Medpace, Inc · 2014 - 2018Risk Factors for Sudden Cardiac Death in Patients with Chronic Kidney Disease
ResearchCo-Mentor · Awarded by National Institutes of Health · 2014 - 2017Computational Approach To Personalized Anemia Management
ResearchPrincipal Investigator · Awarded by University of Louisville · 2012 - 2016BMS CV202-010-0055
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb · 2013 - 2015IPA - Kimberly B. Gitter
ResearchPrincipal Investigator · Awarded by Veterans Administration Medical Center · 2008 - 2010Hemodialysis Vascular Access Clinical Trials Consortium
ResearchCo Investigator · Awarded by National Institutes of Health · 2000 - 2009External Relationships
- Akebia Pharmaceuticals
- AstraZeneca
- ICON CLINICAL RESEARCH PLC
- National Institutes of Health
- Novo Nordisk
- Raleigh Radiology
- Relypsa/Vifor
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.